Liver/Biliary Disorders News

Despite ongoing COVID-19 infection control restrictions, volumes of inpatient consults for alcohol-related gastrointestinal and liver diseases had significantly decreased at the onset of the COVID-19 pandemic, but quickly returned to normal levels, according to an expert presentation during a press conference in advance of Digestive Diseases Week.

Patients with drug-indued liver injury had a long hospital stay, low morbidity and high mortality, according to a study published in the British Journal of Clinical Pharmacology.

The ACG developed recommendations for diagnosis and management of idiosyncratic drug-induced liver injury.

In this video exclusive, Stuart M. Levtiz, MD, discussed the implications he and his team discovered after the case-study of a liver transplant recipient who was reinfected with SARS-CoV-2.

Golexanolone was well tolerated and correlated with improvement in cognitive performance in patients with hepatic encephalopathy, according to a study published in the Journal of Hepatology.

Nonalcoholic fatty liver disease correlated with a significantly increased risk for developing cancer overall, due to the significant increased incidence in hepatocellular carcinoma, according to study results.

It has been well over year since the COVID-19 pandemic began, and all aspects of health care have been impacted in various ways.

Deep learning algorithms outperformed logistic regression models and predicted long-term outcome after liver transplantation with longitudinal data, according to study results.

In this video exclusive, Pol Boudes, MD, chief medical officer of Galectin Therapeutics, spoke about NAVIGATEnash.com, a website for physicians and patients to get information on cirrhosis stemming from nonalcoholic steatohepatitis.

BIO89-100 reduced liver fat in adults with nonalcoholic steatohepatitis, or NASH, while also lowering triglycerides for participants taking weekly and biweekly doses, according to trial data presented at the ENDO annual meeting.